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genda item 117 of the 66th session of the United 
Nations General Assembly was a watershed for 
global health. It marked the adoption by the Gen-
eral Assembly on the 16th of September 2011 of the politi-
cal declaration of the High–level Meeting of the General 
Assembly on the Prevention and Control of Non-commu-
nicable Diseases [1]. The adoption placed non-communi-
cable diseases (NCDs) center stage for global health. To 
reach that point required a significant amount of scientific 
and political effort, first to convene the High–level Meeting 
on NCDs, and then to have the declaration adopted by the 
UN General Assembly. The historical time–line leading up 
to this achievement is punctuated by reflective pieces in a 
number of journals, but dominated by a series in The Lan-
cet [2-8].
One of the interesting features identifiable in the time–line 
is a shift in vocabulary between late 2010 and early 2011 
– a period that is bisected almost exactly by the publication 
of an article, also in The Lancet, identifying “chronicity” as 
the future issue for health systems [9]. Up until late 2011 
the NCDs discussion had 
more often than not used 
the vocabulary of chronic 
diseases rather than NCDs, 
with reference to a typical 
set of non-communicable 
diseases that were chronic 
in nature, including cardio-
vascular diseases (mainly 
heart disease and stroke), 
some cancers, and type 2 di-
abetes [2,3]. Occasionally 
The burden is great and the money little: 
Changing chronic disease 
management in low– and 
middle–income countries
Daniel D. Reidpath, Pascale Allotey
other conditions such as mental health conditions, respira-
tory conditions, injury and such like would appear in the 
narrative. The main conditions, however, were those that 
might be described using a nomenclature of “diseases of 
lifestyle”, related to choices made about smoking, exercise, 
and macro– and micro–nutritional content of food [10-13].
The shift in vocabulary may have just been whimsy, but it 
probably reflected a wish to classify the diseases of interest 
by their causes rather than by their effects or health systems 
consequences (long term management) [14]. The global 
burden of NCDs is significant, and will affect low– and 
middle–income countries most [15]. As a strategy, there is 
no doubt that the greatest future health gains in the area of 
NCDs are going to be made through prevention – which 
requires an understanding of causation – and might then 
support the vocabulary shift. Prevention strategies will have 
to be multifaceted, but may include trying to effect indi-
vidual behaviour change [16,17], change in industrial be-
haviour [18] or change in the environment [19]. Making 
the changes is non-trivial: it will in many cases be harder 
for lower income countries 
to implement; it will take 
time to make the changes; 
and even when the interven-
tions are successful, there 
will  still  be  a  substantial 
number of people who will 
contract non-communicable 
diseases. The health burden 
of NCDs will grow for the 
foreseeable  future;  it  will 
have a real impact on the 
Many health conditions are chronic, and only 
some of those chronic health conditions are 
NCDs.  If the interest is on cause and preven-
tion, then NCDs should be treated separately 
from other chronic diseases.  If the interest is 
on health systems and management, then 
NCDs should be joined with other chronic 
diseases.
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health and non-health budgets of governments; it will have 
an impact on the GDP of countries; and it will have to be 
managed.
Without diminishing the primacy of prevention in global 
health, in this article we want to focus on the practicalities 
of the management of chronic diseases. Note again the shift 
from the NCDs vocabulary back to chronic diseases. This 
is intentional and pointed. If one is interested in under-
standing causes and prevention strategies it is important to 
separate the NCDs from other chronic diseases; however, 
if one is interested in the effects of the diseases, particular-
ly on the health systems, then it is equally important to join 
the NCDs with other chronic diseases [9,14]. Many health 
conditions are chronic, and only some of those chronic 
health conditions are NCDs. Even after the inclusion – 
along with the core non-communicable diseases of cardio-
vascular disease, cancer, and diabetes – the respiratory con-
ditions, mental health conditions, the arthritides, and 
functional loss and disability, there is a group of other dis-
eases that are all chronic in nature. These are the commu-
nicable, infectious diseases that either have no cure, simply 
ongoing management (HIV/AIDS) or they have a cure, but 
the cure takes an extended period of 6 months treatment 
or more (tuberculosis and onchocerciasis – with some 
hope, following recent trials, that a shortened 2–week 
course may be feasible for tuberculosis treatment [20]). The 
commonality is chronicity – the temporal nature of the 
conditions requires an extended relationship with the 
health system, including quite probably an extended finan-
cial relationship.
Most low– and middle–income health systems have been 
designed for the management of maternal and neonatal 
mortality, and acute phases of infectious diseases such as 
malaria, respiratory tract infections, and diarrhoeal diseas-
es [21]. “Receive them, Revive them, and Return them” 
could have been the motto emblazoned over the entrance 
gates to most health services in low and middle income 
countries. The system – beyond a record of immunisation 
or antenatal visits – has not traditionally needed to have a 
memory of the patient. For epidemiological purposes re-
cording health systems interactions is important, but not 
central to the case management. For the acute diseases the 
diagnosis drives most of the decision process. In the man-
agement of chronic diseases, the diagnosis is known early 
in the patient–system relationship, and the ongoing strat-
egy revolves around maintenance, monitoring, encourage-
ment, and compliance (with acute services when neces-
sary). This requires that a relationship is built with the 
client. However, a health system designed to deliver longi-
tudinal management of a chronic health condition is dis-
tinctly different from one designed for the management of 
serial acute episodes.
The two main issues that arise when contemplating health 
systems' management of chronic diseases are structure and 
financing. Unfortunately, the research base for establishing 
evidence for action is thin. We return to the lack of research 
shortly. There is, however, little doubt about the financial 
impact of an increasing chronic disease burden on the in-
dividual, the family, and the health system. Under current 
health systems arrangements, the financing of chronic dis-
ease management in the population is costly, and at a na-
tional level costs will increase with rising prevalence [22]. 
One possibility is that the costs will be carried by individ-
uals through out of pocket payments, which in low– and 
middle–income countries will often have catastrophic con-
sequences for families [23]. Alternatively, costs could be 
carried by government, but few low– and middle–income 
countries could manage the entire financial burden, or 
some mixture of insurance, out of pocket payments, and 
government support.
With respect to the individual and family impact, quotes 
published in a recent article on catastrophic health care 
spending related to acute coronary syndrome in Kerala pro-
vide good examples [23]:
“I am not sure how long I can take my medicines. I have a cred-
it account with the local pharmacy. They also help me out with 
samples from medical representatives. I cannot be a charity case 
forever, can I?”
and
“Right now, I am staying with one of my sisters, so that I don’t 
have to pay rent, water or electricity charges. My other sister 
has cut all ties with me. She fears that I will become a burden 
on her and her family.”
Both these quotes came from the same 50–year–old male 
patient and highlight individual and family collective finan-
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The two main issues that arise when contem-
plating health systems' management of chron-
ic diseases are structure and financing. Our 
interest is in the observation that the manage-
ment of any chronic condition entails a com-
mitment to recurrent costs, which reduces the 
flexibility of health systems to respond to new 
demands. It also requires that a health system 
that traditionally has a poor relationship with 
the population beyond acute management 
becomes more responsive to changes in the 
population health profiles. Such a system will 
be harder for poorer countries to manage than 
richer ones.V
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cial burdens. The disease reduced his daily earning from 
US$ 17 per day to US$ 0.7 per day, and required an in-
crease in expenditure to cover health care (although some 
was available through charity).
The impact on health systems, particularly health systems 
already stretched will be marked. In Kenya, the national 
government believes that the prevalence of type 2 diabetes 
in the population was around 10% in 2008, although “of-
ficial statistics note a diabetes prevalence of 3.5%.” [24]. 
Under some fairly loose assumptions, one can imagine that 
in that 6.5% prevalence gap between what is believed and 
what is officially acknowledged, there is a fairly large group 
of people with insidious diabetes that is damaging their 
eyes, kidneys, and vascular system. For this chronic disease 
alone, the Kenyan government would be anticipating 10% 
of their population should be under clinical management 
(in 2008). Unlike treating a respiratory tract infection, the 
financing of diabetes management is a recurrent cost be-
cause of the chronic nature of the disease. Whence will that 
money come?
At the moment, 61% of the total health spending in Kenya 
goes to another chronic disease – HIV [25]. For that level 
of spending, antiretroviral coverage for 61% of HIV posi-
tive people in need of treatment has been achieved; mean-
ing that 39% of people in need of treatment are missing out 
[26]. The commitment to provision of HIV treatment to 
those in need entails an expansion of services, and an in-
creasing recurrent annual financial commitment that will 
not reduce in the near future. Indeed, given some of the 
evidence on antiretroviral resistance, one might imagine 
the cost will rather increase [27]. Furthermore, the more 
successful one becomes at management, the greater the 
number of people under management, the longer they will 
live, and the greater the recurrent costs.
The purpose here is not to pit one disease against another 
and argue for the greater worthiness of one group of pa-
tients over another. The chronic communicable diseases 
and the chronic non-communicable diseases often have an 
interacting pathophysiology – and the management of one 
supports the management of the other. Both diabetes and 
HIV increase the likelihood of contracting TB [28]. Having 
diabetes increases the likelihood of chronic kidney disease, 
and chronic kidney disease increases the chance of heart 
failure [29]. Our interest is in the observation that the man-
agement of any chronic condition entails a commitment to 
recurrent costs, which reduces the flexibility of health sys-
tems to respond to new demands. It also requires that a 
health system that traditionally has a poor relationship with 
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the population beyond acute management becomes more 
responsive to changes in the population health profiles. 
Such a system will be harder for poorer countries to man-
age that richer ones. The World Health Organization has 
suggested that [22]:
“In order for low– and middle–income country health systems 
to expand individual health–care interventions [for chronic dis-
eases], they need to prioritize a set of low–cost treatments that 
are feasible within their budgets. Many countries could afford a 
regimen of low–cost individual treatments by addressing ineffi-
ciencies in current operations for treating advanced–stage 
NCDs. Experiences from maternal and child health and infec-
tious disease initiatives show that health priorities can be rear-
ranged and low–cost individual treatments improved with only 
a modest injection of new resources.”
Identifying inefficiencies and cost–effective interventions 
to improve health systems performance is laudable. Such 
a strategy will not, however, overcome the fundamental 
bottleneck. Health systems were never designed to treat 
20% or more of a country's population as if they had a dis-
ease all the time. Take two middle–income countries as ex-
amples. In South Africa, the prevalence of HIV in adults is 
about 18% [30], diabetes is about 13% [31], and hyperten-
sion is 10% [32]. In Malaysia, the prevalence of diabetes in 
adults is about 15%, and 25% among one of the ethnic 
groups, the prevalence of hypertension is about 32% [33]. 
It is not enough to find cost–effective strategies for indi-
vidual management. A fundamental rethink is required 
about how population health is managed when a substan-
tial and growing proportion of the population has a chron-
ic disease. We do not have the evidence base for that.
One approach to developing the evidence base is through 
“community health laboratories”. Essentially, within a trac-
table, geographically defined area, such as a county or dis-
trict, health systems innovation can be tested and moni-
tored [34]. Assuming that the entire population has been 
enumerated, and their health status and health systems in-
teraction can be followed over time, it becomes possible to 
measure the impact of health systems innovations on vari-
ous dimensions of health systems performance. Using these 
kinds of community settings, governments can look at im-
plementation within the contexts of real lives and function-
ing communities. This is particularly important in environ-
ments where people employ pluralistic health care engaging 
multiple belief systems simultaneously, utilising both gov-
ernment and private providers. These community based 
research environments are particularly well suited to low– 
and middle–income countries.
In Malaysia, a new health and demographic surveillance 
site, the South East Asia Community Observatory (SEACO), 
is being established with the intention of being able to trial 
health systems innovation relevant to chronic disease man-
agement [35]. There are in excess of 40 health and demo-
graphic surveillance sites in the world, mainly located in 
low–income countries in sub–Saharan Africa [34]. They rely 
on enumerating and then following–up the population over 
time. The raison d'être of HDSS has been in the management 
and prevention of acute health conditions associated with 
vaccine trials, maternal and child health, malaria, diarrhoe-
al diseases, and HIV. Chronic diseases have emerged rela-
tively recently within the scope of HDSS, and no sites had 
been established with this as a theme of interest. SEACO 
has been established with chronic diseases prevention and 
management as a central theme in its development. Unusu-
ally, it is also one of only two HDSS in middle–income coun-
tries.
The value of settings like SEACO is that they sit between 
the unrealistically controlled setting of an experimental tri-
al – focused on the individual and uninterested in the con-
textual effects – and a completely realistic, unmonitored, 
community setting in which context is everything, but the 
impact of change cannot be measured or assessed. Low– 
and middle–income countries, faced with a growing chron-
ic diseases problem will need to rethink how they deliver 
health care – and even what it may mean to deliver health 
care – but they also need an evidence base on which to 
make systems changes. The evidence generated through 
SEACO–like infrastructure has the potential to provide 
novel, yet realistic, models of prevention and health care 
management within the real life context of low– and mid-
dle–income countries. With the growing chronic diseases 
problem this evidence base and new ways of thinking are 
critical to making long term, sustainable systems change. 
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